Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis

Intern Med. 2006;45(18):1033-8. doi: 10.2169/internalmedicine.45.6018. Epub 2006 Oct 16.

Abstract

Objective: This study was aimed to investigate the effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on the acute exacerbation of idiopathic pulmonary fibrosis (IPF).

Patients and methods: Six patients with a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) who developed acute exacerbation were included in this study. Although five of six patients were treated with high-dose corticosteroid therapy, mechanical ventilation was necessary for all six patients due to severe respiratory failure. Blood endotoxin levels were undetectable in all patients. PMX treatment was performed on these six patients.

Results: In four of six patients, alveolar-arterial difference of oxygen (AaDO(2)), serum KL-6 and lactate dehydrogenase (LDH) were improved after PMX treatment. These four patients were successfully weaned from mechanical ventilation and survived more than 30 days after the initial PMX treatment.

Conclusion: These data suggest a potential beneficial effect of PMX treatment on acute exacerbation of IPF.

MeSH terms

  • Acute Disease
  • Aged
  • Antigens, Neoplasm / blood
  • Female
  • Glucocorticoids / therapeutic use
  • Hemoperfusion / methods*
  • Humans
  • L-Lactate Dehydrogenase / blood
  • Male
  • Middle Aged
  • Mucin-1
  • Mucins / blood
  • Oxygen / analysis
  • Pilot Projects
  • Polymyxin B / administration & dosage*
  • Pulmonary Fibrosis / drug therapy*
  • Pulmonary Fibrosis / therapy
  • Respiration, Artificial
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antigens, Neoplasm
  • Glucocorticoids
  • MUC1 protein, human
  • Mucin-1
  • Mucins
  • L-Lactate Dehydrogenase
  • Polymyxin B
  • Oxygen